Effective anti-tumor responses were obtained following the simultaneous use of the Notch inhibitor GSI (DBZ) and the EGFR inhibitor (erlotinib); optimal results were obtained by lowering the dosage of both inhibitors but using them at the same time [102]. The gene discussed is EGFR; the disease is neoplasm.